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SUMMARY 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder. Latest results 
from the literature suggest that genetic factors are involved in the pathogenesis of PD. Several 
mutations and polymorphisms in a number of genes have been provide to have an important 
role in the development of PD. The majority of PD casas are sporadic; only 15-20% of the cases 
are identified as familial. 
The genetic causes and risk factors of PD may serve as important tools through which to attain 
a better understanding of the pathomechanism. However, the vast majority of PD is genetically 
complex, it is caused by the complex interaction of genetic variants in concert with 
environmental factors. Genome-wide association studies have been published numerous PD 
risk loci to date. Particular attention has recently been paid to genes of the vacuolar protein 
sorting-associated protein 35 (VPS35), the glucocerebrosidase (GBA) and the vitamin D 
receptor (VDR). The mutations of these genes were investigated in number of studies, but the 
results are controversial. 
Therefore, in this work, we have examined the p.D620N mutation of the VPS35 gene, which is 
the only confirmed pathogenic VPS35 variant identified to date. Moreover, we have 
investigated the three most common mutations (p.L444P, p.N370S and p.R120W) of the GBA 
and the four most studied polymorphisms (FokI, BsmI, ApaI and TaqI) of VDR gene in 
Hungarian population. 
Since a genetic background is presumed in the development of PD in some cases, it is important 
to investigate the different genetic factors in the various PD populations, which may permit the 
development of new therapeutic targets.  
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1. INTRODUCTION 
1.1 Epidemiology 
Parkinson’s disease (PD) was first described by James Parkinson in 1817 (Parkinson, 2002). 
Nowadays, it is the second most common neurodegenerative disorder after Alzheimer’s disease. 
A meta-analysis revealed that the prevalence of PD is increased with age: 0.05% in individuals 
40 to 49 years; 0.1% in individuals 50 to 59 years; 0.4% in individuals 60 to 69 years; 1.1% in 
individuals 70 to 79 years; and 1.9%  in individuals over age 80 (Pringsheim et al., 2014).  
In the 50 to 59 age group, males had a significant increased prevalence of PD compared to 
females, while in the other age groups,  only a slight male dominance of PD was observed 
(Pringsheim et al., 2014). 
Moreover, it is well known that PD occurs in all ethnic groups around the world and shows 
geographic variability (Zhang and Roman, 1993). Individuals in Asia had a significantly lower 
prevalence of PD compared to individuals in Europe, North America and Australia. The reason 
of geographic variation in the occurrence of PD is unknown, but genetic or environmental 
susceptibilities might explain these findings (Muangpaisan et al., 2011).  
1.2 Pathological and clinical features 
The most prominent neuropathological features of PD are the loss of dopaminergic neurons in 
the substantia nigra (SN) pars compacta and the presence of Lewy bodies, which are 
accumulated and aggregated alpha-synuclein (SNCA) inclusions in the cytoplasm of the 
surviving neurons. The classical motor symptoms like bradykinesia, rigidity, resting tremor and 
late postural instability result directly or indirectly from the dopaminergic deficiency. 
Additionally, many other neuronal pathways not directly involved in motor function (such as 
the noradrenergic locus coeruleus, the serotonergic raphe nuclei, and the cholinergic nucleus 
basalis of Meynert) also show the sign of degeneration (Jellinger, 1991). Therefore, non-motor 
symptoms also appear, like dementia, depression, anxiety and autonomic dysfunctions 
(Pfeiffer, 2016). 
Although the precise pathomechanism of PD is still not fully understood, several molecular 
mechanisms of neuronal death in PD pathogenesis have been described including mitochondrial 
dysfunction, oxidative stress, microglia activation and inflammation. With regard to 
aetiological background, the most common concepts is that PD may result from complex 
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interaction between environmental factors, genetic background, and aging (Burbulla and 
Kruger, 2011). 
1.3 Environmental risk factors 
Environmental exposures seem to play an important role in the development of PD. The 
discovery of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in 1983 provided the 
first proof that an environmental toxin could lead to parkinsonism in human (Langston et al., 
1983). This toxin can cause the selective damage of the cells in the SN by inhibition of 
mitochondrial complex I (Singer and Ramsay, 1990). Moreover, epidemiological studies 
provided evidence that the chronic exposure of pesticides, metals and solvents could increase 
the risk of developing PD (Gorell et al., 1998, Jankovic, 2005, Gatto et al., 2009). However, 
there is no conclusive evidence proving that any environmental toxin causes PD. Smoking has 
been inversely associated with susceptibility to PD, but smoking does not appear to have any 
effect on disease progression or prevention (Gorell et al., 1999, Alves et al., 2004). 
1.4 Genetics of Parkinson’s disease 
Monogenic forms of PD 
Parkinson’s disease is classified into familiar and sporadic groups. The majority of PD cases 
are sporadic; only 15-20% of the cases are identified as familial. Nevertheless, in most 
populations up to 5%-10% of patients carry mutations in monogenic forms. So far, 21 loci have 
been identified in familial PD (Table 1.). The PARK designations refer to monogenic forms of 
autosomal dominant PD (PARK1/4, PARK3, PARK5, PARK8, PARK11, PARK13, PARK17, 
PARK18, and PARK21), and autosomal recessive PD (PARK2, PARK6, PARK7, PARK9, 
PARK14, PARK15, PARK19 and PARK20) (Coppede, 2012). 
The relationship between mutations in several of these genes and PD is uncertain. However, 
several genes suggest that abnormal handling of misfolded proteins by the ubiquitin-proteasome 
and autophagy-lysosomal system, increased oxidative stress, mitochondrial and lysosomal 
dysfunction contribute to PD development (Kalinderi et al., 2016). 
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Locus Gene Inherit. 
type 
Mutation Disorder 
PARK1/4 
(4q21-22) 
SNCA AD p.A30P, p.E46K and 
pA53T substitution and 
CNVs 
EOPD, progressive, 
levodopa responsive 
parkinsonism with 
dementia 
PARK2 
(6q25.2-
27) 
Parkin AR Homozygous/ 
compound 
heterozygous missense 
(>57) and exonic CNVs 
EOPD, slow progression, 
responsive to levodopa, 
with early dyskinesias 
PARK3 
(2q13) 
Unknown AD N/A Classical PD 
PARK5 
(4p13) 
UCHL1 AD p.I93M substitution Classical PD 
PARK6 
(1p35-36) 
PINK1 AR Missense and exonic 
CNVs 
EOPD, slow progression, 
responsive to levodopa, 
some with dyskinesias 
PARK7 
(1p36) 
DJ-1 AR Homozygous missense 
and deletion 
(delEX1-5) mutations, 
compound 
heterozygotes 
EOPD, slow progression, 
levodopa responsive 
PARK8 
(12q12) 
LRRK2 AD Several mutations, 
Substitutions; 
p.R1441C/G, 
p.Y1699C, p.G2019S 
and p.I2020T 
Classical PD, 
predominantly levodopa 
responsive 
PARK9 
(1p36) 
ATP13A2 AR Homozygous/ 
compound 
heterozygous CNVs 
Kufor-Rakeb syndrome; 
atypical PD with 
dementia, spasticity, and 
gaze palsy 
PARK10 
(1p32) 
Unknown N/A N/A Classical PD 
PARK11 
(2q36-37) 
GIGYF2? AD Missense mutation LOPD 
PARK12 
(Xq21-25) 
Unknown X-
linked 
N/A Classical PD 
PARK13 
(2q12) 
OMI/HTRA2 AD p.G399S Classical PD 
PARK14 
(22q13.1) 
PLA2G6 AR Homozygous/ 
compound 
heterozygous 
EOPD with dyskinesias, 
levodopa responsive 
PARK15 
(22q12-
13) 
FBXO7 AR Homozygote and 
compound heterozygote 
mutations 
Juvenile parkinsonism, 
severe phenotype with 
spasticity and dementia 
PARK16 
(1q32) 
Unknown N/A 
 
N/A Classical PD 
PARK17 
(16q11.2) 
VPS35 AD p.D620N Classical PD 
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PARK18 
(3q27.1) 
EIF4G1 AD Missense mutations 
 
Classical PD 
PARK19 
(1p31.3) 
DNAJC6 
(auxilin) 
AR Homozygote/ 
compound heterozygote 
mutation  
Juvenile parkinsonism 
PARK20 
(21q22.11) 
SYNJ1 
(synaptojanin 
1) 
AR Homozygote missense 
mutation: p.R258Q 
Juvenile parkinsonism 
with mental retardation 
PARK21 
(3q22.1)  
DNAJC13 AD p.N855S  LOPD 
Table 1. PARK loci and genes associated with familial forms of PD 
AD: autosomal dominant, AR: autosomal recessive, CNV: copy number variant, EOPD: early-
onset Parkinson’s disease, LOPD: late-onset Parkinson’s disease 
PARK1/4: α-synuclein (SNCA) 
SNCA was discovered first to play a role in PD. In 1996, a genome wide linkage analysis 
mapped the PARK1 locus on chromosome 4q21 (Polymeropoulos et al., 1996). A year later, 
the first missense mutation (p.A53T) in the SNCA gene was identified as the cause of disease 
in Italian and Greek families with autosomal dominant PD (Polymeropoulos et al., 1997). Then, 
two additional rare missense mutations, p.A30P (c.88C>G) and p.E46K (c.188G>A) were 
discovered in German and Spanish families respectively (Kruger et al., 1998, Zarranz et al., 
2004) . The three missense mutations in the SNCA gene alter the function of the protein and are 
believed to promote aggregation of the protein (Conway et al., 1998, Choi et al., 2004). 
Besides these mutations, multiplication of the SNCA gene was also associated with familial 
cases of PD. SNCA duplications found in French families with milder clinical phenotype 
(Chartier-Harlin et al., 2004), in Japanese families and in three apparently sporadic PD patients 
from Korea (Nishioka et al., 2006, Ahn et al., 2008). SNCA triplications were identified in an 
American and Swedish-American patients (Farrer et al., 2004). SNCA multiplications are 
associated with increased α-synuclein mRNA and protein in brain tissues (Farrer et al., 2004). 
PARK2: Parkin 
One year later after the discovery of SNCA, PARK2 locus was mapped to chromosome 6q25-
27 in Japanese family with autosomal recessive juvenile parkinsonism and the causative gene 
was identified as parkin (Kitada et al., 1998). Until now, numerous mutation have been 
published including point mutations, frameshift mutations, deletions, and multiplication of 
exons (Abbas et al., 1999, Hedrich et al., 2004). Parkin gene mutations are there the most 
common autosomal recessive mutations in the early onset PD. Parkin mutations have been 
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identified in up to 50% of familial cases and in 18% of sporadic diseases (Schulte and Gasser, 
2011).  
Parkin is an E3 ubiquitin ligase. The mutant parkin causes a loss of normal E3 ligase activity 
leading to the accumulation of its substrates such as synphilin-1, synaptotagmin XI and Hsp70 
(Shimura et al., 2000). 
PARK6: PTEN-induced kinase 1 (PINK1) 
In 2001, PARK6 locus was mapped on chromosome 1p35-36 in an Italian family with 
autosomal recessively inherited form of PD (Valente et al., 2001). Later, two homozygous point 
mutations (p.G309A and p.W437X) in the PINK1 gene were described in two families with 
early onset and slowly progressive PD (Valente et al., 2004). Today, more than 25 pathogenic 
mutations were identified already. The frequency of these mutations in PD patients is between 
0.5% and 9% in various populations (Bonifati et al., 2005, Ibanez et al., 2006). 
PINK1 is a mitochondrial kinase, which protects cells against oxidative stress induced apoptosis 
(Valente et al., 2004). Mutant PINK1 can lead to apoptosis of dopaminergic cells (Zhou et al., 
2014). 
PARK7: DJ-1 
PARK7 locus was identified on chromosome 1p36. In 2003, a large deletion (delEX1-5) and a 
missense mutation (p.L166P) were reported in two families, leading to identification of DJ-1 
gene as a causative gene for familial PD with recessive inheritance (van Duijn et al., 2001, 
Bonifati et al., 2002). Mutations in DJ-1 are responsible for 1-2% of EOPD cases (Bonifati et 
al., 2003). DJ-1 is a multifunctional protein that participates in antioxidative protection and 
mitochondrial function (Ariga et al., 2013).  
PARK8: Leucine-rich repeat kinase 2 (LRRK2)  
PARK8 locus was mapped on chromosome 12 in a Japanese family with ADPD in 2002 
(Funayama et al., 2002). The gene has 51 exons encode a large 2527 amino acid protein, which 
contains several domains. In 2004, 2 groups identified the discovery of mutations in LRRK2 
gene. It has been reported that mutations in the different domains results in variable pathological 
changes (Zimprich et al., 2004). Since then, many missense mutations have been identified in 
LRRK2, but the pathogenicity is only clearly for seven of them (Healy et al., 2008). The 
common feature is neuronal loss and gliosis in the SN. The LRRK2 mutations constitute around 
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10% of the familial PD cases, with a clear autosomal dominant inheritance pattern (Healy et 
al., 2008).  
 
PARK17: vacuolar protein sorting associated protein 35 (VPS35) 
The VPS35 gene, which is involved in the development of many neurodegenerative diseases, 
including Alzheimer’s disease and PD (Small et al., 2005, Deng et al., 2013), is localized to 
16q11.2, and various mutations have been reported in it (Zhang et al., 2000). The gene encodes  
the vacuolar sorting protein homolog, which is a key component of the retromer complex and 
is involved in the retrograde transport of proteins from endosomes to the trans-Golgi network 
(Bonifacino and Hurley, 2008).  
Amongst the mutations of the VPS35 gene, the p.D620N missense mutation has recently been 
reported to be pathogenic for PD (Vilarino-Guell et al., 2011, Zimprich et al., 2011, Williams 
et al., 2017), mainly in the autosomal dominantly inherited cases, but it has additionally been 
detected in some sporadic PD cases (Vilarino-Guell et al., 2011, Zimprich et al., 2011, Ando et 
al., 2012, Kumar et al., 2012, Lesage et al., 2012, Sheerin et al., 2012). The p.D620N mutation 
was found in 5 familial and 2 sporadic cases (Sharma et al., 2012). In contrast, other studies 
suggest that there is no such mutation in SPD in the Caucasian population (Kumar et al., 2012, 
Sheerin et al., 2012). The mutation carriers have been estimated to account for less than 1% of 
the PD population. Additional rare VPS35 variants (i.e. P316S, R524W, I560T, H599R and 
M607V) may also be linked to PD, although their pathogenicity remains unclear (Sharma et al., 
2012, Deng et al., 2013). 
Genetic risk factor of PD 
Monogenic forms represent less than 10% of PD in most populations. Apart from monogenic 
forms of PD, genetic risk factors would stand out as the cause of disease as well, affecting the 
age at onset and progression, possibly in combination with environmental factors. Genome-
wide association studies (GWAS) have focused on identifying genetic variability serving risk 
for PD. 
Among the identified risk factors for PD, consistent associations have been demonstrated for 
SNCA, LRRK2 and MAPT (Labbe and Ross, 2014). In addition, heterozygous mutations in the 
GBA gene have been validated as a genetic susceptibility factor for PD (Kalinderi et al., 2016).  
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SNCA 
The role of genetic variants in SNCA gene have been identified in number of studies from 
various populations. Point mutations and CNVs are rare in sporadic cases (Johnson et al., 2004). 
However, genetic polymorphisms in the promoter and toward the 3’ end of the gene was 
associated with sporadic PD (Pals et al., 2004, Mueller et al., 2005). In addition, an allele length 
variation (SNCA Rep1) has also been associated with an increased risk for PD (Maraganore et 
al., 2006). 
LRRK2 
Two LRRK2 variants appear to be risk variants for PD in Asian populations, but it could not 
confirmed in other populations. The p.G2385R polymorphism is associated with the increased 
risk for PD in Taiwan, Chinese, Japanese and a Korean populations (Di Fonzo et al., 2006, 
Farrer et al., 2007, Funayama et al., 2007, Kim et al., 2010). The second LRRK2 risk allele is 
the p.R1628P variant. It seems to increase the risk of PD twofold in Chinese populations, but 
this variant was not associated with PD in Malays (Tan et al., 2008). In 2011, Ross and 
colleagues identified a new variant (p.M1646T) in Caucasian individuals, which showed a 
higher risk for PD (Ross et al., 2011). 
MAPT: microtubule-associated protein tau 
The MAPT gene mutations were initially identified as causative for frontotemporal dementia 
with parkinsonism linked to chromosome 17 (Hutton et al., 1998). To date, large number of 
mutations have been reported in this gene, causing parkinsonian symptoms (Ludolph et al., 
2009), although pathogenic mutations have not been found in PD.  
MAPT locus has two common haplotype groups, termed H1 and H2 (Stefansson et al., 2005). 
Associations between these haplotypes and risk for PD has been investigated in number of 
studies, and the results show an association between the H1 haplotype and PD (Pastor et al., 
2000, Skipper et al., 2004, Zabetian et al., 2007). A join effects between genetic variants in 
SNCA and in the MAPT gene has been described; the combination of risk genotypes in SNCA 
and MAPT doubles the risk of PD (Goris et al., 2007). 
GBA: glucocerebrosidase 
Gaucher’s disease (GD) is an autosomal recessively inherited glycolipid storage disorder 
caused by a deficiency of the lysosomal enzyme GBA. The most common clinical presentation 
is liver damage, however, there are other features of the disease, like neurological 
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manifestations (Wong et al., 2004). GD is classified into three types: type 1, the most common 
form, has no associated neurological symptoms; type 2, or acute neuropathic disease, displays 
severe neurological involvement leading to death within the first years of life; type 3, or chronic 
neuronopathic GD, exhibits varying degrees of systemic involvement with at least one 
neurological manifestation (Hruska et al., 2006, Dandana et al., 2016). 
The GBA gene is localized at chromosome 1q21, and comprises 11 exon encoding a 497 amino 
acid protein. So far, more than 300 mutations of this gene have been identified, including point 
mutations, deletions, and recombination alleles derived from a nearby located pseudogene 
(Hruska et al., 2008) (Figure 1). Regarding the phenotype, many of these mutations have been 
classified as “null”, “mild” or “severe”, depending on the resulting level of GBA production. 
Null mutation (c.84dupG) do not lead to any enzyme production. Mild mutations, such as 
p.N370S, are associated with type 1 disease. Severe mutations, such as p.L444P, result in 
enzyme production and are associated with type 2 or 3 (Beutler et al., 2005).  
 
 
Figure 1. The exonic structure of GBA gene and positions of 13 common mutations. 
The phenotype of GD and PD do not normally overlap, but the first indication for a relationship 
between the two disease come from clinical observation. Until recently, several studies have 
reported a clinical, neuropathological or genetic association between GD and PD (Clark et al., 
2007, Lesage et al., 2011, Brockmann and Berg, 2014). First, Neudorfer et al. described that 
GD patients and their relatives frequently had parkinsonism (Neudorfer et al., 1996, Goker-
Alpan et al., 2004). This examination led to conclusion that the heterozygous mutations of GBA 
gene may be a risk factor for PD.  
Numerous genotyping studies have demonstrated associations between several GBA mutations 
and PD in different ethnic groups. As an example, the frequencies of GBA mutations in PD 
patients were highest amongst Ashkenazi Jews (ranging from 13.7% to 31.3%) (Aharon-Peretz 
et al., 2004, Clark et al., 2005, Gan-Or et al., 2008). Furthermore, several studies have indicated 
that a high frequency of GBA mutations is related to an increased risk of PD amongst Japanese, 
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Canadian, Portuguese, Greek, Norwegian, Italian, Serbian and Chinese populations (Sato et al., 
2005a, Toft et al., 2006, De Marco et al., 2008, Bras et al., 2009, Mitsui et al., 2009, Moraitou 
et al., 2011, Wang et al., 2012, Zhang et al., 2012, Kumar et al., 2013). A recent meta-analyses 
have revealed that GBA variants are the most common genetic risk factors associated with PD, 
increasing the risk of PD ~5 fold, and the three most frequent mutations in non-Ashkenazi 
Jewish PD patients are p.N370S, p.L444P and p.R120W (Sidransky et al., 2009).  
Although the precise mechanisms between GBA mutations and the development of PD is still 
unknown, some hypotheses have been reported to explain it, including loss-of-function and 
gain-of-function theories. 
The loss-of-function theories focus on altered lipid metabolism. It has been detected that SNCA 
binds to lipids in the plasma membrane and synaptic vesicles (Jo et al., 2000). The binding of 
lipids may be protect the fibrillar forms of SNCA and inhibit the aggregation of this protein. It 
has been supposed that mutant GBA protein lead enzymatic deficiency which may alter the 
sphingolipid composition of membranes and disturbed membrane binding of SNCA, thereby 
increasing its accumulation in the cytoplasm (Li et al., 2015). 
The gain-of-function theories suppose that the missense mutations of GBA result in a misfolded 
protein. The GCase dysfunction might lead to lysosomal insufficiency, thereby reducing SNCA 
degradation (Li et al., 2015).  
Both theories postulate reduced enzyme activity of GCase, therefore it was investigated in 
number of studies (Gegg and Schapira, 2018). GCase enzyme activity was significantly reduced 
in the SN (58%), putamen (48%), amygdala (40%) and cerebellum (47%) in PD-GBA patients 
(Gegg et al., 2012).  Similar results were observed in fibroblasts from patients with GD and 
heterozygous mutation carriers with or without PD compared to control (McNeill et al., 2014). 
Moreover, GCase activity from fresh blood was measured in PD patients with and without GBA 
mutations, and GD patients. GBA mutation carriers PD patients had a lower GCase enzyme 
activity (median 16 nmol/mg protein/hour) compared to non-carriers (median 28.5 nmol/mg 
protein/hour) (Ortega et al., 2016). 
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Other PD-associated genes  
Besides the causative genes and risk factors, several polymorphisms in various genes were 
described which associated with PD, like BACE1, PITX3 and COX2 (Liu et al., 2011, Dai et 
al., 2015, Lange et al., 2015). Furthermore, several researches were focused on VDR gene and 
identified some polymorphic variants which may be associated with PD (Niu et al., 2015). 
VDR: vitamin D receptor 
Vitamin D, as an environmental factor, has been the subject of various studies on different 
neurological disorders, from which it has emerged that a vitamin D deficiency is associated 
with an increased risk of many diseases, including schizophrenia, autism, multiple sclerosis, 
Alzheimer’s disease and PD (Sato et al., 1997, Sato et al., 1998, McGrath, 1999, Munger et al., 
2006, Newmark and Newmark, 2007, Cannell, 2008, Evatt et al., 2008, Ascherio et al., 2010, 
Buell et al., 2010, Mowry, 2011, Orton et al., 2011, Amezcua et al., 2012). 
In humans, the majority of vitamin D is synthesized via the cleavage of a cholesterol metabolite 
in the epidermis by UVB, with further metabolism to the primary circulating form of vitamin 
D, 25-hydroxyvitamin D (25OHD), in the liver. This compound circulates in the blood in a 
form bound to vitamin D binding protein and in the kidneys 25OHD is metabolized by 1-α-
hydroxylase to its active form, 1,25-dihydroxyvitamin D (1,25OHD). 1,25OHD binds to 
vitamin D receptors (VDRs) and influences calcium homeostasis, neurotrophic signalling, 
immunoregulation, cell growth and differentiation (Kato, 2000, Dusso et al., 2005, Kesby et al., 
2011).  
Besides these molecular mechanisms, epidemiological evidence have shown the potential value 
of vitamin D in PD prevention. The level of vitamin D in PD has been analysed in number of 
studies. A Japanese population exhibited a higher incidence of hip fractures and lower serum 
levels of 25OHD in PD patients as compared with the healthy controls (Sato et al., 1997, Sato 
et al., 2005b), observations that were confirmed in a Caucasian population (Evatt et al., 2008). 
The serum 25OHD level correlated negatively with the severity of PD, measured in terms of 
the Hoehn & Yahr (HY) stage and the Unified Parkinson’s Disease Rating Scale (UPDRS) 
(Sato et al., 1997, Sato et al., 2005b, Suzuki et al., 2012). Whereas Sato et al. (Sato et al., 2005b) 
reported a negative correlation between the 1,25OHD level and the UPDRS score, Suzuki et al. 
(Suzuki et al., 2012) could not confirm this finding. Later, a clinical trial in Japan directly 
demonstrated that vitamin D supplementation reduced the risk of PD development (Knekt et 
al., 2010) and prevented the deterioration of HY stage in PD patients (Suzuki et al., 2013) . 
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The VDR gene encodes a nuclear transcription factor, and widely expressed in the nervous 
system. The highest expression level is found in the SN (Eyles et al., 2005). 
The human gene is localized to 12q12 and various polymorphisms have been reported in it 
(Zmuda et al., 2000) (Figure 2).  
 
 
Figure 2. Schematic diagram of human VDR gene with the polymorphic sites. 
 
 
Among the polymorphisms, BsmI, ApaI, TaqI and FokI are the most studied polymorphisms.  
However, only limited data are available regarding the association between VDR 
polymorphisms and PD, and the results have been contradictory. Suzuki et al. (Suzuki et al., 
2012) found that FokI CC genotype was associated with milder forms of PD in a Japanese 
population. Furthermore, an association between the BsmI bb genotype and PD was 
demonstrated in a Korean population (Kim et al., 2005). A recent genome-wide association 
study revealed the association of VDR polymorphisms with the risk of PD and the age at onset 
in a Caucasian population (Butler et al., 2011). In a Chinese study it was described that FokI C 
allele associates with an increased risk of PD as well as early-onset PD (Han et al., 2012). 
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2. AIMS OF THE WORK 
Several causative genes have been identified, including VPS35, which are associated with PD. 
Besides causative genes, genetic risk factors and several polymorphisms in various genes have 
been reported which play a role in the development of PD, like mutations of GBA and VDR 
genes. The mutations were investigated in Caucasian population, mainly in Western and 
Northern Europe, but the results are controversial, and is well known, that the distribution of 
the mutations show geographical and ethnical variations. Moreover, there are only limited data 
from the Middle and Eastern Europe. Previously, the most frequent PD causing LRRK2 
p.G2019S mutation was investigated in a Hungarian PD patient group, but there are no study 
has been conducted previously to assess the frequency of VPS35, GBA or VDR gene mutations 
in Hungarian PD patients. 
The general aim of our work was to determine the frequency of some PD associated mutations 
in the Hungarian population, which belongs to the Caucasian race. 
The specific aims of the work were: 
 To investigate whether the p.D620N mutation of the VPS35 gene is present in SPD in 
the Hungarian population. 
 To analyse the possible association between p.L444P, p.N370S and p.R120W mutations 
of the GBA gene in PD patients and controls. To investigate relationship between age 
at onset in the PD patients and GBA mutations. 
 To examine the genotype distribution of VDR ApaI, FokI, TaqI or BsmI polymorphisms 
in Hungarian PD patients and controls. Moreover, we want to analyse the possible 
associations between the age at onset, the male-female ratio and the VDR 
polymorphisms in the PD group. 
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3. MATERIAL AND METHODS 
3.1 Subjects 
3.1.1 VPS35 and GBA mutations analysis 
124 SPD patients and 122 healthy control subjects were enrolled in the study. The demographic 
characteristics of the patient and control populations are summarized in Table 2. The study 
group were age-matched.  
 PD group  Control group  
No. 124 122 
Age (years, mean ± SD) 66.5 ± 9.5 64.3 ± 8.2 
Age at onset ≤ 60 years 67 (54%) N.A. 
Age at onset > 60 years 57 (46%) N.A. 
Table 2. Characteristics of groups of PD patients and controls 
 
3.1.2 Detection of VDR polymorphisms 
The demographic data of the patient and control groups are presented in Table 3. 100 SPD 
patients and 109 age-matched healthy controls were enrolled the analysis of VDR 
polymorphisms. 
 PD group (%) Control group (%) 
No. 100 109 
Age (mean±SEM) 66.4±9.3 64.0±8.2 
Age at onset ≤ 60 
Age at onset > 60 
52 (52) 
48 (48) 
N.A. 
N.A. 
Gender  
Male 
Female 
 
44 (44) 
56 (56) 
 
54 (49.5) 
55 (50.5) 
Table 3. Characteristics of PD patients and healthy controls in VDR polymorphism analysis 
 
All of the patients were examined by movement disorder specialists, who confirmed the 
diagnosis of SPD. Patients with secondary parkinsonism were excluded. The PARK2 and 
PARK8 mutations were not present in the assessed patient population. Early-onset PD (EOPD) 
was defined as an age at onset ≤ 60 years and late-onset PD (LOPD) as an age at onset > 60 
years. The control group individuals had no history of neurological or psychiatric disorders. All 
the patients with SPD and all the controls were of Hungarian origin and were selected from the 
Department of Neurology at the University of Szeged. 
20 
 
The study protocol was approved by the Medical Research Council Scientific and Research 
Ethics Committee (47066-3/2013/EKU (556/2013)) and Ethics Committee of the Faculty of 
Medicine (22/2012), University of Szeged. All study participants gave their written informed 
consent in accordance with the Helsinki Declaration. 
3.2 DNA isolation 
From all participants peripheral blood was taken from a cubital vein in a tube with EDTA and 
stored 4°C. Genomic DNA was extracted by a standard desalting method (Miller et al., 1988), 
and stored at –20 °C until further use. 
All polymorphisms were determined by polymerase chain reaction (PCR) techniques in a 
thermal cycler (Applied Biosystems 2720 Thermal Cycler, Applied Biosystems, Foster City, 
CA, USA) and restriction fragment-length polymorphism (RFLP). 
3.3 Detection of VPS35 mutation 
The p.D620N mutation of VPS35 gene were amplified with previously described PCR 
conditions and primers (Sudhaman et al., 2013): forward primer 5’- AGG CTG CAG AAG 
TCT CAC AGG A-3’and reverse primer 5’- AGG GCA GGG GGA CAG TGA AGA-3’. The 
PCR conditions were: 95 °C for 2 min, 95 °C for 30 s, 58 °C for 30 s and 72 °C for 45 s for 35 
cycles, and finally 72 °C for 7 min. The PCR products were digested with the HinFI restriction 
enzyme (Thermo Scientific, Waltham, MA, USA) at 37 °C for 30 min. The digested products 
were separated by agarose gel electrophoresis. The genotypes were defined as GG (257 bp, 231 
bp, 139 bp, 74 bp, and 18 bp), GA (257 bp, 231 bp, 213 bp, 139 bp, 74 bp, and 18 bp) or AA 
(257 bp, 231 bp, 213 bp, and 18 bp). 
3.4 Analysis of GBA mutations 
Three previously described primer pairs were used separately to amplify the DNA region of 
each mutation (Aharon-Peretz et al., 2004, Wu et al., 2007).  
PCR amplification of the polymorphic p.L444P site (rs421016) was performed with the 
following primers: forward 5’-GGA GGA CCC AAT TGG GTG CGT-3’ and reverse 5’-ACG 
CTG TCT TCA GCC CAC TTC-3’. The PCR conditions were as follows: 95 °C for 10 min, 
95 °C for 30 s, 59 °C for 30 s and 72 °C for 1 min for 35 cycles, and finally 72 °C for 5 min. 
After the PCR reaction, the products were digested with the restriction enzyme NciI (Fermentas, 
21 
 
Vilnius, Lithuania) at 37 °C overnight. Fragments were separated by electrophoresis in 2% 
stained agarose gels and visualized in UV light. The genotypes were defined as AA (637 bp), 
GG (535 and 102 bp) or AG (637, 535 and 102 bp).  
Previously published primers were used to detect the p.R120W (rs397515515) mutation:  
forward 5’-GCA GAG TCC CAT ACT CTC CT-3’ and reverse 5’-TGG GTG ACA GAG AGA 
GAG ACT-3’. The PCR conditions differed only the annealing temperature from the p.L444P 
mutation used conditions. Here the annealing temperature was 56 °C. The PCR products were 
digested with NciI restriction enzyme at 37 °C overnight to identify the genotypes. The digested 
fragments were visualized in 2 % stained agarose gel: CC (454, 300 and 82 bp), CT (536, 454, 
300 and 82 bp) and TT (536 and 300 bp). 
The p.N370S (rs76763715) polymorphisms of the GBA gene were determined by using the 
following primers and PCR conditions: forward 5’-GCC TTT GTC CTT ACC CTC†G-3’, 
reverse 5’-GAC AAA GTT ACG CAC CCA A-3’; 95 °C for 10 min, 95 °C for 30 s, 53 °C for 
30 s and 72 °C for 30 s for 35 cycles, and finally 72 °C for 5 min. † A mismatch was introduced 
in the primer at one nucleotide to create a restriction site. 
Following amplification, the products were digested with XhoI at 37°C overnight and 
electrophoresed on 4% agarose gels. The absence of restriction site on both alleles result in 105 
bp fragments (AA). The presence of the restriction site on both alleles (CC) led to 89 and 16 
bp. In case of heterozygotes (CT), the presence of all three bands (105, 89 and 16 bp) needed. 
3.5 Genotyping of VDR polymorphisms 
For amplification of the FokI C/T polymorphism (rs10735810) the following primers were used 
(Harris et al., 1997): forward primer 5’-AGC TGG CCC TGG CAC TGA CTC TGC TCT-3’ 
and reverse primer 5’-ATG GAA ACA CCT TGC TTC TTC TCC CTC-3’. The PCR 
amplification was carried out with the following cycling parameters: 95 °C for 5 min, and then 
30 cycles of 95 °C for 30 s, 60 °C for 30 s, and 72 °C for 30 s, and finally 72 °C for 7 min. The 
PCR products were digested with the FokI restriction enzyme (Fermentas, Vilnius, Lithuania) 
at 55 °C for 3 h. The digested products were separated by agarose gel electrophoresis. The 
genotypes were defined as CC (265 bp), TT (169 and 96 bp) or CT (265, 169 and 96 bp). 
The BsmI A/G polymorphic site of intron 8 (rs1544410) was amplified with previously 
described primers (Kim et al., 2005): forward primer 5’-CAA CCA AGA CTA CAA GTA CCG 
CGT CAG TGA-3’ and reverse primer 5’-AAC CAG CGG GAA GAG GTC AAG GG-3’. The 
PCR conditions were as follows: 95 °C for 10 min, 95 °C for 30 s, 59 °C for 30 s and 72 °C for 
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50 s for 35 cycles, and finally 72 °C for 10 min. The PCR products were digested with the 
restriction enzyme Mva12691 (Fermentas, Vilnius, Lithuania) at 37 °C overnight. Fragments 
were separated by electrophoresis in 2 % stained agarose gels and visualized in UV light. The 
genotypes were defined as AA (825 bp), GG (650 and 175 bp) or AG (825, 650 and 175 bp). 
PCR amplification of the polymorphic TaqI T/C site (rs731236) was performed with the 
following primers (Riggs et al., 1995): forward 5’-CAG AGC ATG GAC AGG GAG CAA-3’ 
and reverse 5’-CAC TTC GAG CAC AAG GGG CGT TAG C-3’. The PCR conditions were 
identical to those for the BsmI polymorphism. The PCR products were digested with the TaqI 
restriction enzyme (Fermentas, Vilnius, Lithuania) at 65 °C for 3 h and fragments were analysed 
by electrophoresis in 2 % agarose gel. The absence of the TaqI restriction site on both alleles 
(TT) led to the 501 bp fragment, whereas the presence of the restriction site on both alleles (CC) 
yielded bands of 295 and 206 bp. The presence of the 501, 295 and 206 bp fragments reflected 
the TC heterozygotes. 
The ApaI G/T polymorphic site (rs7976091) was amplified with previously described primers 
(Sainz et al., 1997): forward primer 5’-CAA CCA AGA CTA CAA GTA CCG CGT CAG 
TGA-3’ and reverse primer 5’-CAC TTC GAG CAC AAG GGG CGT TAG C-3’ The PCR 
conditions were: 95 °C for 10 min, followed by 35 cycles of 95 °C for 30 s, 59 °C for 30 s and 
72 °C for 2 min, and finally 72 °C for 7 min. The PCR products were incubated with the ApaI 
restriction enzyme (Fermentas, Vilnius, Lithuania) at 37 °C overnight. The genotypes were 
defined as TT (absence of restriction site, one band at 2000 bp), TG (heterozygote, three bands 
at 2000, 1700 and 300 bp) and GG (presence of the restriction site, two bands at 1700 and 300 
bp). 
3.6. Statistical analysis 
SPSS software version 22.0 was applied for the evaluation of the data populations (SPSS Inc., 
Chicago, IL, USA). The genotype frequencies in the patients and the controls were analysed by 
using the Fisher exact test or the χ2 test. The normality of the data was checked with the 
Kolmogorov-Smirnov test. Since the data exhibited Gaussian distribution, and the Levene test 
did not reveal significant differences in the homogeneity of variances, we applied the 
independent t test for the comparison of the difference in age between the PD groups and the 
controls. The associations between the genotypes and the PD were estimated via the odds ratio 
(OR), with a 95% confidence interval (CI) (95% CI). A p value of less than 0.05 was considered 
statistically significant. The observed FokI, BsmI, ApaI and TaqI genotype frequencies were in 
accordance with the Hardy–Weinberg equilibrium in both the patients and the controls. 
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4. RESULTS 
4.1 VPS35 gene mutation 
The common VPS35 p.D620N mutation was not detected either in the PD patients or in the 
controls in the assessed population (Table 4). 
 Genotype  
 GG (%) GA (%) AA (%)  
PD patients 124 (100) 0 (0) 0 (0) 
 
Control 122 (100) 0 (0) 0 (0) 
Table 4. Distribution of p.D620N mutation in the PD patients and the control group 
4.2 GBA gene mutations 
Among PD patients, 3 individuals (2.4%) carried a heterozygous mutant GBA allele: in all 3 
cases the p.L444P substitution. In contrast, no mutations were detected in the control group. 
The difference in mutation frequencies between the patients (2.4%) and controls (0%) was not 
statistically significant (p = 0.247) (Table 5). However, the carriers of the GBA mutation were 
at an increased risk of developing PD (OR = 6.05, 95% CI 0.300 to 122.06).  
 Genotype  
 AA (%) AG (%) GG (%) p 
PD patients 121 (97.6) 3 (2.4) 0 (0) 
0.247 
Control 122 (100) 0 (0) 0 (0) 
Table 5. GBA p.L444P genotypes distributions in patients with PD and controls 
Moreover, all the patients who carried the mutant allele were in the EOPD group. The frequency 
was significantly higher in the EOPD group than in the controls (p=0.042). However, a 
comparison of the frequency between the EOPD group and the LOPD group failed to reveal 
any difference (p = 0.247) (Table 6). 
 AA (%)  AG (%) GG (%) p 
Age at onset 
≤60 yr 
>60 yr 
 
64 (95.5) 
57 (100) 
 
3 (4.5) 
0 (0) 
 
0 (0) 
0 (0) 
 
0.247 
Table 6. Relationship between age at onset in the PD patients as a function of the GBA p.L444P 
genotyping 
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Neither the p.R120W nor the p.N370S variant of the GBA gene was identified among the 
assessed PD cases and controls (Table 7.). 
 R120W     N370S     
 CC (%) CT (%) TT (%)   TT (%) TC (%) CC (%)    
PD patients 124 (100) 0 (0) 0 (0)   124 (100) 0 (0) 0 (0)   
 
Control 122 (100) 0 (0) 0 (0)   122 (100) 0 (0) 0 (0)   
Table 7. Distribution of R120W and N370S mutations of GBA gene in patients with PD and 
controls 
 
4.3 VDR polymorphisms 
VDR FokI polymorphism 
The distributions of FokI restriction site genotypes in the PD patients and the controls are shown 
in Table 8. There was a significant difference in genotypes between the PD patients and the 
healthy controls (χ2 = 6.7; p = 0.035). The frequency of genotype with C (CC+CT) was 
significantly higher among the patients with PD relative to the controls: OR = 2.677 and 95% 
CI = 1.214-5.91, p = 0.015 for CC+CT vs. TT. Moreover, the C allele showed a significant 
association with PD group (OR = 1.615, 95% CI = 1.087-2.399, p = 0.017). There was no 
difference between the FokI polymorphism and gender in PD group, and no significant 
association was found between this polymorphism and the age at onset (Table 9). 
 Genotype  Allele frequency 
 CC (%) CT (%) TT (%) p C (%) T (%) p 
PD patients 42 (42) 48 (48) 10 (10) 
0.035 
132 (66) 68 (34) 
0.017 
Control 35 (32.1) 49 (45) 25(22.9) 119 (54.6) 99 (45.4) 
Table 8. VDR FokI genotypes and allele frequencies in the PD patients and the controls 
 
 CC (%)  CT (%) TT (%) p 
Age at onset 
≤60 yr 
>60 yr 
 
22 (42.3) 
20 (41.7) 
 
24 (46.2) 
24 (50) 
 
6 (11.5) 
4 (8.3) 
 
0.841 
Gender  
Male 
Female 
 
18 (40.9) 
24 (42.9) 
 
22 (50) 
26 (46.4) 
 
4 (9.1) 
6 (10.7) 
 
0.958 
Table 9.  Relationship between age at onset and gender in the PD patients as a function of the 
VDR FokI genotyping 
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VDR BsmI polymorphism 
There was no significant difference in the BsmI genotypic distribution (OR = 0.890, 95% CI = 
0.478-1.654, p = 0.753 for GG vs. AA+AG) and allele frequency (OR = 0.977, 95% CI = 0.665-
1.434, p = 0.905) between the PD patients and the healthy controls. The BsmI genotypic 
distribution, the allele frequency, the male to female ratio and the age at onset of the PD patients 
are presented in Table 10. 
 
Genotype Allele frequency 
 AA (%) AG (%) GG (%) p A (%) G (%) p 
PD patients 
Controls 
24 (24) 
25 (22.9) 
49 (49) 
57 (52.3) 
27 (27) 
27 (24.8) 
0.902 
97 (48.5) 
107 (49) 
103 (51.5) 
111 (51) 
0.905 
Age at onset 
≤60 yr 
>60 yr 
 
9 (17.3) 
15 (31.3) 
 
27 (51.9) 
22 (45.8) 
 
16 (30.8) 
11 (22.9) 
 
0.261 
   
Gender  
Male 
Female 
 
7 (15.9) 
17 (30.4) 
 
22 (50) 
27 (48.2) 
 
15 (34.1) 
12 (21.4) 
 
0.161 
   
Table 10. VDR BsmI genotypes and allele distributions in patients with PD and controls 
 
VDR TaqI polymorphism 
The frequencies of the TaqI genotype in the PD group and the controls were similar (OR = 
0.840, 95% CI = 0.399-1.767, p = 0.646 for TT+TC vs. CC) and we did not find differences in 
allele distribution (OR = 0.802, 95% CI = 0.540-1.190, p = 0.273). There was no significant 
difference in the male to female ratio and the age at onset in the various TaqI polymorphism 
subgroups (Table 11). 
 
 Genotype  Allele frequency 
 TT (%) TC (%)  CC (%) p T (%) C (%) p 
PD patients 
Controls 
35 (35) 
47 (43.1) 
48 (48) 
46 (42.2) 
17 (17) 
16 (14.7) 
0.485 
118 (59) 
140 (64.2) 
82 (41) 
78 (35.8) 
0.273 
Age at onset 
≤60 yr 
>60 yr 
 
22 (42.3) 
13 (27.1) 
 
23 (44.2) 
25 (52.1) 
 
7 (13.5) 
10 (20.8) 
 
0.265 
   
Gender 
Male 
Female 
 
18 (40.9) 
17 (30.4) 
 
20 (45.5) 
28 (50) 
 
6 (13.6) 
11 (19.6) 
 
0.528 
   
Table 11. VDR TaqI genotypes and allele frequencies in patients with PD and controls 
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VDR ApaI polymorphism 
The ApaI genotype frequencies (OR = 1.352, 95% CI = 0.654-2.796, p = 0.466 for GG vs. 
TT+TG) and the allele distribution (OR = 1.177, 95% CI = 0.793-1.748, p = 0.417) were similar 
in the healthy controls and the patients with PD. There was no statistically significant 
association between the ApaI polymorphism and the age at onset in PD patients, and no 
significant difference was found between this polymorphism and gender in the PD group (Table 
12). 
 
Genotype  Allele frequency 
 TT (%) TG (%) GG (%) p T (%) G (%) p 
PD patients 
Controls 
42 (42) 
42 (38.5) 
43 (43) 
46 (42.2) 
15 (15) 
21 (19.3) 
0.691 
127 (63.5) 
130 (59.6) 
73 (36.5) 
88 (40.4) 
0.417 
Age at onset 
≤60 yr 
>60 yr 
 
18 (34.6) 
24 (50) 
 
23 (44.2) 
20 (41.7) 
 
11 (21.2) 
4 (8.3) 
 
0.130 
   
Gender 
Male 
Female 
 
13 (29.5) 
29 (51.8) 
 
22 (50) 
21 (37.5) 
 
9 (20.5) 
6 (10.7) 
 
0.07 
   
Table 12. VDR ApaI genotypes and allele frequencies in the PD patients and the controls 
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5. DISCUSSION 
PD is a frequent and heterogeneous disorder. The majority of PD cases (80-85%) are sporadic; 
the remaining 15-20% of the patients have a familial history. The precise patomechanism of 
PD is not fully understood, therefore the treatment poses a great challenge for clinical 
investigation. For this reason, it would be important to determine genetic alterations may 
promote the selection of homogenous subpopulations, hereby a target specific therapy would 
be enable in the different subgroups. It is well known, that the environmental factors influence 
the development of PD, but the sensibility to environmental factors is mostly determined by 
genetic and epigenetic background. 
 
Molecular genetics has identified several genes which linked to monogenic forms of PD with 
autosomal dominant or autosomal recessive inheritance.  
Although the monogenic forms less than 10% of Mendelian cases, these genes also play an 
important role in the pathogenesis of sporadic forms of PD (Dawson and Dawson, 2010, Lubbe 
and Morris, 2014). To date, the frequent PD causing LRRK2 p.G2019S mutation was examined 
in Hungarian PD patients, but this mutation has not been detected in anyone (Balicza et al., 
2012).  
p.D620N mutation of VPS35 gene in PD 
VPS35 is a subunit of retromer complex and is involved in endosomal-lysosomal trafficking.  
Recent studies focused on the link between the retromer complex and PD and have been 
investigated in different model organisms. Decreased VPS35 levels 
in Drosophila dopaminergic neurons were shown to lead to locomotor defects and shortened 
lifespan (Linhart et al., 2014). In addition, the expression of the VPS35 with p.D620N mutation 
in the rat brain was shown to cause a dopaminergic neuron degeneration (Tsika et al., 2014). 
Furthermore, the p.D620N mutation in VPS35 (PARK17) was recently discovered as a new 
cause of PD, mainly in the autosomal dominantly inherited cases, although it may additionally 
have a role in SPD, but the results are inconsistent (Vilarino-Guell et al., 2011, Zimprich et al., 
2011). The frequency of the mutation carriers have been estimated ranging from 0.1% to 1% of 
the PD population (Kumar et al., 2012). The distribution of the VPS35 mutation shows ethnic 
differences; the p.D620N mutation is more frequent in Yemenite Jews (1.67%), in France 
(1.2%), in Tunisia (0.5%), and in Austria (0.4%), however this mutation has not been found in 
other ethnicities, like in Canada, Norway, Ireland, Taiwan, Chinese and Greeks (Deng et al., 
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2013, Kalinderi et al., 2015). Noticeably, this mutation has been examined in a number of 
Caucasian populations with different results. Therefore, we investigated the presence of the 
p.D620N mutation of the VPS35 gene in Hungarian SPD patients, but we were unable to 
identify this mutation in any of the investigated patients or controls indicating that the frequency 
is less than 0.8%. This data is similar to those of previous studies that have reported associations 
between this mutations and PD in other Caucasian populations. This suggests that the p.D620N 
mutation of the VPS35 gene is a rare cause of SPD.  
 
Association between GBA mutations and PD 
Besides the Mendelian genes, several studies have focused on genetic variability conferring 
susceptibility to sporadic PD. GWAS studies are carried out to identify rare genetic variants 
that increase the risk of PD. Multiple GWAS in PD patients and controls have revealed 
numerous loci, including GBA and MAPT, as risk factors for sporadic PD (Vacic et al., 2014).  
GBA gene encode a lysosomal enzyme and several mutation have been reported in it. The 
precise mechanisms underlying the relation between the mutations of GBA and the 
development of PD is still indefinable. Recent studies provide some perspectives; the link 
among GBA mutations, GCase activity, and SNCA has made an important contribution in the 
pathogenesis of PD (Li et al., 2015).  
Several studies have reported that the frequencies of GBA mutations are higher in PD patients 
(5-10%) than in controls, but the range varies in different ethnic groups (Schapira, 2015). 
p.L444P is the most common variant among non-Ashkenazi Jewish patients. Our results 
indicated that the PD patients demonstrated a higher frequency (2.4%) of the p.L444P mutation 
of the GBA gene as compared with the controls (0%), although the difference was not 
statistically significant. This finding is similar to those of previous studies that have reported 
associations between the p.L444P mutation and PD (Wu et al., 2007, Mao et al., 2010, Wang 
et al., 2012). The p.L444P mutation was shown to occur at incidences of 2%, 1.39% and 1.14% 
among American non-Jewish, Canadian and British PD patients, respectively (Sato et al., 
2005a, Clark et al., 2007, Neumann et al., 2009). Moreover, an Eastern Canadian study 
concluded that the frequency of p.L444P was higher among PD patients (3.1%) as compared 
with controls (Han et al., 2016).  
A number of studies have found that GBA mutations may be considered a risk factor, mainly 
in EOPD cases (Clark et al., 2007, Wu et al., 2007, Gonzalez-Del Rincon Mde et al., 2013). 
Our study revealed that all the patients who carried the mutant allele were in the EOPD group. 
In accordance with our data higher p.L444P frequency was observed in some other European 
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EOPD population, like Greece (3.3%), Spain (2.66%), and United Kingdom (1.15%) (Kalinderi 
et al., 2009, Neumann et al., 2009, Seto-Salvia et al., 2012). These data emphasized the 
significance of the GBA mutation, particularly in EOPD cases. 
Besides the p.L444P mutation, the other two most frequent genetic alterations in non-Ashkenazi 
Jewish patients are p.N370S and p.R120W (Sidransky et al., 2009), and we therefore 
investigated these two GBA mutations too. p.N370S has been demonstrated to be the most 
common mutation among  Ashkenazi Jewish PD patients (14.1%), and it is also the most 
frequent mutation in several European (e.g. Serbian (1.9%), French (2.9%) and Portuguese 
(2.2%)) populations (Bras et al., 2009, Sidransky et al., 2009, Lesage et al., 2011, Kumar et al., 
2013). A significant association between the p.R120W mutation and PD have been detected in 
a Japanese study (Mitsui et al., 2009). In contrast, we did not detect either the p.R120W or the 
p.N370S variant of the GBA gene among the PD cases and the controls, although the p.N370S 
mutation was earlier demonstrated in some European PD patients (Sidransky et al., 2009, 
Moraitou et al., 2011, Kumar et al., 2013). Our findings suggest that the frequency of these 
mutations are less than 0.8% in the investigated PD populations, more precise frequency could 
be determined by increasing of the sample size. 
These diverse data suggest that the Caucasian population is not homogeneous in this respect.  
 
Association between VDR mutations and PD 
Earlier reports revealed that 25OHD levels were decreased in PD patients in Japanese and 
Caucasian populations (Sato et al., 1997, Sato et al., 2005b, Evatt et al., 2008) and demonstrated 
a higher incidence of osteoporosis in PD patients of both genders, with a decreased bone mass 
index and a reduced bone mineral density (Fink et al., 2005, Sato et al., 2005b). Overall, it has 
been clearly shown that the vitamin D metabolism is affected in PD patients. Additionally, 
differences have also been demonstrated in the VDR polymorphisms in PD in Japanese, 
Korean, Chinese and Caucasian populations (Kim et al., 2005, Butler et al., 2011, Han et al., 
2012, Suzuki et al., 2012).  
Our results have indicated a significant difference in the FokI genotype distribution between 
PD and controls in Hungarian population; the frequency of the C allele was significantly higher 
in PD patients than in the healthy control group, suggesting that the C allele may have a role in 
the development of PD. Previously, a Japanese and a Chinese study detected difference in this 
polymorphism between healthy subjects and PD patients. In Japan, FokI CC genotype was 
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associated with mild PD (Suzuki et al., 2012).  Han et al. (Han et al., 2012) suggested that FokI 
C allele might be a risk factor for sporadic PD development.  
FokI polymorphism is located in exon 2 at the 5′ coding region of the gene. This polymorphism 
results in different translation initiation sites:  if the VDR gene contains C allele, the protein 
will be three amino acids shorter. Difference in length may result in altered VDR function (Arai 
et al., 1997, Zmuda et al., 2000). 
BsmI, ApaI and TaqI polymorphisms are located in the 3’-end region of the VDR gene, which 
do not result in changes in the amino acid sequence of the VDR (Zmuda et al., 2000). We did 
not identify significant associations with these VDR polymorphisms. A Korean study detected 
difference in the genotype frequency of BsmI polymorphism between healthy subjects and PD 
patients; the bb genotype in that study was more common in Korean PD patients than in controls 
(Kim et al., 2005). No difference in BsmI polymorphism was identified in Japanese patients 
(Suzuki et al., 2012), where the FokI CC genotype displayed a strong association with the mild 
PD.  
Our data demonstrated that there are no significant associations between VDR ApaI 
polymorphism and PD, whereas the ApaI polymorphism was associated with the EOPD in 
American Caucasians. Interestingly, there was no association between FokI polymorphism and 
PD patients among American Caucasians, reflecting differences in ethnicity among Caucasians 
(Butler et al., 2011). We did not detect an association between the age at onset, the male-female 
ratio and the VDR polymorphisms in the PD group. These diverse data suggest that the 
Caucasian population is not homogeneous in this respect. 
As far as we are aware, this is the first report on the potential correlation between a VDR 
polymorphism and PD from a European country. 
Since our data, a Taiwanese and a Faore Island study described no relationship between VDR 
polymorphisms and the risk of PD (Lin et al., 2014, Petersen et al., 2014). Furthermore, two 
recent meta-analysis indicated that the VDR BsmI, ApaI and TaqI polymorphisms are not 
associated with PD (Zhang et al., 2014, Niu et al., 2015) while the FokI polymorphism possibly 
associated with increased risk of PD (Niu et al., 2015). These data confirm our findings that the 
VDR FokI polymorphism increase the risk of PD. 
 
The differences between the results of the various studies might stem from the different sample 
size and the different study populations with the possibility of certain ethnic variations.  
The results suggest that the genetic analysis of SPD patients is important, because it could help 
to understand the development of PD and the design of future therapeutic studies. 
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6. CONCLUSION 
We investigated some mutations and polymorphisms which may associated with PD in 
Hungarian population. In this work, we have provided evidence at the first time that p.D620N 
mutation of VPS35 gene is not involved in the pathogenesis of the investigated Hungarian SPD 
patients. In contrast, p.L444P mutation of GBA gene showed a significant association with 
EOPD. Furthermore, a significant correlation were detected between FokI polymorphism of 
VDR gene and the investigated PD population.  
As far as we aware, this is the first work on the potential association between a GBA mutation, 
VDR polymorphism and PD from Hungarian population.  
The detection of the different genetic factors in the various PD group is important, because it 
may permit the development of new therapeutic targets. Furthermore, the identification of novel 
genetic risk factors may facilitate a better selection of homogeneous subpopulations for 
therapeutic studies. 
Our study has limitations; the sample size is relatively small, therefore the detection of the rare 
genetic mutations are difficult. In the future we plan to increase the number of subject in the 
examination to be able to detect this rare mutations in PD patients even more representatively. 
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• Genotyping  for  four  polymorphic  sites  in the  VDR  gene  in patients  with  Parkinson’s  disease.
• Association  was  detected  between  FokI  C polymorphism  and  Parkinson’s  disease.
• No  association  could  be  detected  between  ApaI,  BsmI,  TaqI  polymorphisms  and  Parkinson’s  disease.
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a  b  s  t  r  a  c  t
Vitamin  D  receptor  (VDR)  gene  encodes  a transcription  factor  that  inﬂuences  calcium  homeostasis  and
immunoregulation,  and  may  play  a  role  in  neurological  disorders  including  Parkinson’s  disease  (PD).
The investigations  of  the  association  between  VDR  and  PD  in  different  populations  revealed  various
results.  In a  present  study  100  PD  patients  and  109 healthy  controls  from  the  Hungarian  population  were
genotyped  for  four  polymorphic  sites  (BsmI,  ApaI,  FokI  and  TaqI)  in  the  VDR  gene.  The  polymorphisms
were  determined  by  polymerase  chain  reaction  and  restriction  fragment  length  polymorphism  (PCR-
RFLP).  Our  results  demonstrate  an association  between  the  FokI  C  allele  and  PD;  the  frequency  of  the  C
allele was  signiﬁcantly  higher  in  PD  patients  than  in controls,  suggesting  that  this  polymorphism  may
have  a role  in  the  development  of  PD  in  these  patients.
© 2013 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Parkinson’s disease (PD) is one of the most common neurode-
generative disorders. The characteristic neuropathological features
are the presence of Lewy bodies and the loss of dopaminergic cells
in the substantia nigra pars compacta, but the precise pathomech-
anism is still not fully understood. The most common concepts are
related to the genetic background and environmental effects [5].
Indeed, a number of genetic risk factors and gene–environment
interactions have been implicated in the pathogenesis of PD
[13,14,19–21,24,25,29,37]. Vitamin D, as an environmental factor,
has been the subject of various studies on different neurological
disorders, from which it has emerged that a vitamin D deﬁciency
is associated with an increased risk of many diseases, including
schizophrenia, autism, multiple sclerosis, Alzheimer’s disease and
PD [1,3,4,7,9,22,26–28,30,33,35].
∗ Corresponding author. Tel.: +36 62 545348; fax: +36 62 545597.
E-mail address: klivenyi.peter@med.u-szeged.hu (P. Klivenyi).
In humans, the majority of vitamin D is synthesized via the
cleavage of a cholesterol metabolite in the epidermis by UVB, with
further metabolism to the primary circulating form of vitamin D,
25-hydroxyvitamin D (25OHD), in the liver. This compound cir-
culates in the blood in a form bound to vitamin D binding protein
and in the kidneys 25OHD is metabolized by 1--hydroxylase to its
active form, 1,25-dihydroxyvitamin D (1,25OHD). 1,25OHD binds
to vitamin D receptors (VDRs) and inﬂuences calcium homeostasis,
neurotrophic signaling, immunoregulation, cell growth and differ-
entiation [8,16,17]. Both 1--hydroxylase and VDRs are expressed
in numerous body tissues, including the brain [10].
The VDR gene encodes a nuclear transcription factor. The human
gene is localized to 12q12 and various polymorphisms have been
reported in it [38]. The level of vitamin D in PD has been analyzed
in number of studies. A Japanese population exhibited a higher
incidence of hip fractures and lower serum levels of 25OHD in PD
patients as compared with the healthy controls [34,35], observa-
tions that were conﬁrmed in a Caucasian population [9]. The serum
25OHD level correlated negatively with the severity of PD, mea-
sured in terms of the Hoehn &Yahr stage and the Uniﬁed Parkinson’s
0304-3940/$ – see front matter ©  2013 Elsevier Ireland Ltd. All rights reserved.
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Table  1
Characteristics of PD patients and healthy controls.
PD group (%) Control group (%)
No. 100 109
Age (mean ± SEM) 66.4 ± 9.3 64.0 ± 8.2
Age  at onset ≤60 52 (52)
Age at onset >60 48 (48)
Gender
Male 44 (44) 54 (49.5)
Female 56 (56) 55 (50.5)
Disease Rating Scale (UPDRS) [34–36]. Whereas Sato et al. [34]
reported a negative correlation between the 1,25OHD level and the
UPDRS score, Suzuki et al. [36] could not conﬁrm this ﬁnding.
However, only limited data are available regarding the associa-
tion between VDR polymorphisms and PD. Suzuki et al. [36] found
that FokI CC genotype was associated with milder forms of PD in
a Japanese population. Furthermore, an association between the
BsmI bb genotype and PD was demonstrated in a Korean popu-
lation [18]. A recent genome-wide association study revealed the
association of VDR polymorphisms with the risk of PD and the age
at onset in a Caucasian population [6]. In a Chinese study it was
described that FokI C allele associates with an increased risk of PD
as well as early-onset PD [12].
The study we report here related to whether the known VDR
gene polymorphisms ApaI, FokI, TaqI and BsmI are associated with
PD in the Hungarian population, which belongs to the Caucasian
race.
2. Materials and methods
2.1. Subjects
100 idiopathic PD patients (mean age: 66.4 ± 9.3 yr; 44 men
and 56 women) were enrolled. The patients were evaluated by
movement disorders specialists, who conﬁrmed the diagnosis of
idiopathic PD. Secondary forms of parkinsonism were excluded.
The age at onset was determined from the medical records and
the cases were categorized as early-onset (diagnosed ≤60 yr) or
late-onset (diagnosed >60 yr) PD (Table 1). The Park2 and LRRK2
mutations were not present.
The control group comprised 109 healthy individuals (mean
age: 64.0 ± 8.2 yr; 54 men  and 55 women) who had no history
of neurological or psychiatric disorders (Table 1). The patients
and healthy controls, all of Hungarian origin, were selected from
the Department of Neurology and Department of Medical Micro-
biology and Immunobiology at the University of Szeged. The
study was approved by the Ethics Committee of the Faculty of
Medicine, University of Szeged. All study participants gave their
written informed consent, in accordance with the Declaration of
Helsinki.
2.2. DNA isolation
Genomic DNA was isolated from the peripheral blood by a
standard desalting method [23], and stored at −20 ◦C until further
use.
The VDR polymorphisms were determined by polymerase chain
reaction (PCR) techniques in a thermal cycler (Applied Biosystems
2720 Thermal Cycler, Applied Biosystems, Foster City, CA, USA) and
restriction fragment-length polymorphism (RFLP).
2.3. Genotyping
For ampliﬁcation of the FokI C/T polymorphism (rs10735810)
the following primers were used [15]: forward primer 5′-AGC TGG
CCC TGG CAC TGA CTC TGC TCT-3′ and reverse primer 5′-ATG GAA
ACA CCT TGC TTC TTC TCC CTC-3′. The PCR ampliﬁcation was  car-
ried out with the following cycling parameters: 95 ◦C for 5 min, and
then 30 cycles of 95 ◦C for 30 s, 60 ◦C for 30 s, and 72 ◦C for 30 s, and
ﬁnally 72 ◦C for 7 min. The PCR products were digested with the FokI
restriction enzyme (Fermentas, Vilnius, Lithuania) at 55 ◦C for 3 h.
The digested products were separated by agarose gel electrophore-
sis. The genotypes were deﬁned as CC (265 bp), TT (169 and 96 bp)
or CT (265, 169 and 96 bp).
The BsmI A/G polymorphic site of intron 8 (rs1544410) was
ampliﬁed with previously described primers [18]: forward primer
5′-CAA CCA AGA CTA CAA GTA CCG CGT CAG TGA-3′ and reverse
primer 5′-AAC CAG CGG GAA GAG GTC AAG GG-3′. The PCR con-
ditions were as follows: 95 ◦C for 10 min, 95 ◦C for 30 s, 59 ◦C for
30 s and 72 ◦C for 50 s for 35 cycles, and ﬁnally 72 ◦C for 10 min. The
PCR products were digested with the restriction enzyme Mva12691
(Fermentas, Vilnius, Lithuania) at 37 ◦C overnight. Fragments were
separated by electrophoresis in 2% stained agarose gels and visu-
alized in UV light. The genotypes were deﬁned as AA (825 bp), GG
(650 and 175 bp) or AG (825, 650 and 175 bp).
PCR ampliﬁcation of the polymorphic TaqI T/C site (rs731236)
was  performed with the following primers [31]: forward 5′-CAG
AGC ATG GAC AGG GAG CAA-3′ and reverse 5′-CAC TTC GAG CAC
AAG GGG CGT TAG C-3′. The PCR conditions were identical to
those for the BsmI polymorphism. The PCR products were digested
with the TaqI restriction enzyme (Fermentas, Vilnius, Lithuania)
at 65 ◦C for 3 h and fragments were analyzed by electrophoresis
in 2% agarose gel. The absence of the TaqI restriction site on both
alleles (TT) led to the 501 bp fragment, whereas the presence of the
restriction site on both alleles (CC) yielded bands of 295 and 206 bp.
The presence of the 501, 295 and 206 bp fragments reﬂected the TC
heterozygotes.
The ApaI G/T polymorphic site (rs7976091) was  ampliﬁed with
previously described primers [32]: forward primer 5′-CAA CCA AGA
CTA CAA GTA CCG CGT CAG TGA-3′ and reverse primer 5′-CAC TTC
GAG CAC AAG GGG CGT TAG C-3′. The PCR conditions were: 95 ◦C
for 10 min, followed by 35 cycles of 95 ◦C for 30 s, 59 ◦C for 30 s and
72 ◦C for 2 min, and ﬁnally 72 ◦C for 7 min. The PCR products were
incubated with the ApaI restriction enzyme (Fermentas, Vilnius,
Lithuania) at 37 ◦C overnight. The genotypes were deﬁned as TT
(absence of restriction site, one band at 2000 bp), TG (heterozygote,
three bands at 2000, 1700 and 300 bp) and GG (presence of the
restriction site, two  bands at 1700 and 300 bp).
2.4. Statistical analysis
All statistical analyses were performed with the SPSS Statis-
tics 17.0 software (SPSS Inc., Chicago, IL, USA). The difference in
genotype frequencies was  analyzed by using the Fisher’s exact
test or the 2 test. The associations between the genotypes and
the PD were estimated via the odds ratio (OR), with a 95%
conﬁdence interval (CI) (95% CI). A p value of less than 0.05
was  considered statistically signiﬁcant. The observed FokI, BsmI,
ApaI and TaqI genotype frequencies were in accordance with the
Hardy–Weinberg equilibrium in both the patients and the con-
trols.
3. Results
3.1. VDR FokI polymorphism
The distributions of FokI restriction site genotypes in the PD
patients and the controls are shown in Table 2. There was a sig-
niﬁcant difference in genotypes between the PD patients and the
healthy controls (2 = 6.7; p = 0.035). The frequency of genotype
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Table 2
VDR FokI genotypes and allele frequencies in the PD patients and the controls.
Genotype Allele frequency
CC (%) CT (%) TT (%) p C (%) T (%) p
PD patients 42 (42) 48 (48) 10(10) 0.035 132 (66) 68(34) 0.017
Control 35 (32.1) 49 (45) 25(22.9) 119 (54.6) 99 (45.4)
Table 3
Relationship between age at onset and gender in the PD patients as a function of the
VDR  FokI genotyping.
CC (%) CT (%) TT (%) p
Age at onset
≤60 yr 22 (42.3) 24 (46.2) 6 (11.5) 0.841
>60 yr 20 (41.7) 24 (50) 4 (8.3)
Gender
Male 18 (40.9) 22 (50) 4 (9.1) 0.958
Female 24 (42.9) 26 (46.4) 6 (10.7)
with C (CC + CT) was signiﬁcantly higher among the patients with
PD relative to the controls: OR = 2.677 and 95% CI = 1.214–5.91,
p = 0.015 for CC + CT vs. TT. Moreover, the C allele showed a signif-
icant association with PD group (OR = 1.615, 95% CI = 1.087–2.399,
p = 0.017). There was no difference between the FokI polymorphism
and gender in PD group, and no signiﬁcant association was  found
between this polymorphism and the age at onset (Table 3).
3.2. VDR BsmI polymorphism
There was no signiﬁcant difference in the BsmI genotypic dis-
tribution (OR = 0.890, 95% CI = 0.478–1.654, p = 0.753 for GG vs.
AA + AG) and allele frequency (OR = 0.977, 95% CI = 0.665–1.434,
p = 0.905) between the PD patients and the healthy controls. The
BsmI genotypic distribution, the allele frequency, the male to
female ratio and the age at onset of the PD patients are presented
in Table 4.
3.3. VDR TaqI polymorphism
The frequencies of the TaqI genotype in the PD group and the
controls were similar (OR = 0.840, 95% CI = 0.399–1.767, p = 0.646
for TT + TC vs. CC) and we did not ﬁnd differences in allele distri-
bution (OR = 0.802, 95% CI = 0.540–1.190, p = 0.273). There was no
signiﬁcant difference in the male to female ratio and the age at
onset in the various TaqI polymorphism subgroups (Table 5).
3.4. VDR ApaI polymorphism
The ApaI genotype frequencies (OR = 1.352, 95%
CI = 0.654–2.796, p = 0.466 for GG vs. TT + TG) and the allele
distribution (OR = 1.177, 95% CI = 0.793–1.748, p = 0.417) were
similar in the healthy controls and the patients with PD (Table 6).
There was no statistically signiﬁcant association between the
ApaI polymorphism and the age at onset in PD patients, and no
signiﬁcant difference was found between this polymorphism and
gender in the PD group.
4. Discussion
This work involved a study of VDR polymorphism in PD patients
among Hungarians. Earlier reports revealed that 25OHD levels were
decreased in PD patients in Japanese and Caucasian populations
[9,34,35] and demonstrated a higher incidence of osteoporosis in
PD patients of both genders, with a decreased bone mass index and
a reduced bone mineral density [11,34]. Overall, it has been clearly
shown that the vitamin D metabolism is affected in PD patients.
Table 4
VDR BsmI genotypes and allele distributions in patients with PD and controls.
Genotype Allele frequency
AA (%) AG (%) GG (%) p A (%) G (%) p
PD patients 24 (24) 49 (49) 27 (27) 0.902 97 (48.5) 103 (51.5) 0.905
Controls 25 (22.9) 57 (52.3) 27 (24.8) 107 (49) 111 (51)
Age  at onset
≤60 yr 9 (17.3) 27 (51.9) 16 (30.8) 0.261
>60  yr 15 (31.3) 22 (45.8) 11 (22.9)
Gender
Male 7 (15.9) 22 (50) 15 (34.1) 0.161
Female 17 (30.4) 27 (48.2) 12 (21.4)
Table 5
VDR TaqI genotypes and allele frequencies in patients with PD and controls.
Genotype Allele frequency
TT (%) TC (%) CC (%) p T (%) C (%) p
PD patients 35 (35) 48 (48) 17 (17) 0.485 118(59) 82(41) 0.273
Controls 47 (43.1) 46 (42.2) 16 (14.7) 140(64.2) 78(35.8)
Age  at onset
≤60 yr 22 (42.3) 23 (44.2) 7 (13.5) 0.265
>60 yr 13 (27.1) 25 (52.1) 10 (20.8)
Gender
Male 18 (40.9) 20 (45.5) 6 (13.6) 0.528
Female 17 (30.4) 28 (50) 11 (19.6)
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Table  6
VDR ApaI genotypes and allele frequencies in the PD patients and the controls.
Genotype Allele frequency
TT (%) TG (%) GG (%) p T (%) G (%) p
PD patients 42 (42) 43 (43) 15 (15) 0.691 127 (63.5) 73 (36.5) 0.417
Controls 42 (38.5) 46 (42.2) 21 (19.3) 130 (59.6) 88 (40.4)
Age  at onset
≤60 yr 18 (34.6) 23 (44.2) 11 (21.2) 0.130
>60 yr 24 (50) 20 (41.7) 4 (8.3)
Gender
Male 13 (29.5) 22 (50) 9 (20.5) 0.07
Female 29 (51.8) 21 (37.5) 6 (10.7)
Differences have also been demonstrated in the VDR poly-
morphisms in PD in Japanese, Korean, Chinese and Caucasian
populations [6,12,18,36].
Our results have indicated a signiﬁcant difference in the FokI
genotype distribution between PD and controls in Hungarian pop-
ulation; the frequency of the C allele was signiﬁcantly higher in PD
patients than in the healthy control group, suggesting that the C
allele may  have a role in the development of PD.
Previously, a Japanese and a Chinese study detected difference
in this polymorphism between healthy subjects and PD patients.
In Japan, FokI CC genotype was associated with milder forms of PD
[36]. Han et al. [12] suggested that FokI C allele might be a risk factor
for sporadic PD development.
FokI polymorphism is located in exon 2 at the 5′ coding region of
the gene. This polymorphism results in different translation initia-
tion sites: if the VDR gene contains C allele, the protein will be three
amino acids shorter. Difference in length may  result in altered VDR
function [2,38].
BsmI, ApaI and TaqI polymorphisms are located in the 3′-
end region of the VDR gene, which do not result in changes
in the amino acid sequence of the VDR [38]. We  did not iden-
tify signiﬁcant associations with these VDR polymorphisms. A
Korean study detected difference in the genotype frequency of
BsmI polymorphism between healthy subjects and PD patients;
the bb genotype in that study was more common in Korean PD
patients than in controls [18]. No difference in BsmI polymor-
phism was identiﬁed in Japanese patients [36], where the FokI CC
genotype displayed a strong association with the milder forms of
PD.
Our data demonstrated no signiﬁcant associations between VDR
ApaI polymorphism and PD, whereas the ApaI polymorphism was
associated with the early-onset form of PD in American Caucasians.
Interestingly, there was no association between FokI polymor-
phism and PD patients among American Caucasians, reﬂecting
differences in ethnicity among Caucasians [6].
These diverse data suggest that the Caucasian population is not
homogeneous in this respect. We  did not detect an association
between the age at onset, the male–female ratio and the VDR poly-
morphisms in the PD group. The differences between the results of
the various authors must be interpreted with regard to the facts that
the study populations and sample sizes differed, with the additional
possibility of certain ethnic variations.
As far as we are aware, this is the ﬁrst report on the potential
correlation between a VDR polymorphism and PD from a Euro-
pean country. We  conclude overall that the C allele of the VDR FokI
polymorphism may  be associated with PD in a Caucasian popula-
tion.
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• Mutations  of  GBA  and  the VPS35  gene  have been  investigated  in a Hungarian  PD  population.
• Heterozygous  mutation  (L444P)  of  GBA  was found  in  2.4% of the  PD  cases  (0% in  the controls).
• All the PD  patients  who  carried  the  mutations  were  in the  EOPD  group.
• No  association  was  detected  between  the D620N  mutation  of  the  VPS35  gene  and  PD.
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a  b  s  t  r  a  c  t
Parkinson’s  disease  (PD)  is the second  most  common  neurodegenerative  disorder,  with  cases  of either
familial  or  sporadic  origin.  Several  polymorphisms  in  a  number  of genes  have  been  proved  to have an
important  role  in the  development  of  PD. Particular  attention  has  recently  been  paid to  genes  of  the
glucocerebrosidase  (GBA)  and  the vacuolar  protein  sorting-associated  protein  35 (VPS35).
In this  study,  the  three  most  common  mutations  (L444P,  N370S  and  R120W)  of the  GBA  gene  and  the
D620N  mutation  of  the  VPS35  gene  were examined  in 124 Hungarian  patients  diagnosed  with  sporadic
PD  (SPD)  and  122  control  subjects.
The frequency  of  the  L444P mutation  of  the GBA  gene  proved  to be  higher  in the  PD patients  (2.4%)  than
in  the  controls  (0%),  although  the  difference  was  not  statistically  signiﬁcant.  All  the  patients  who  carried
the  mutant  allele  were  in  the  early-onset  PD  (EOPD)  group.  However,  neither  the  R120W  nor  the  N370S
variant  of the  GBA  gene  nor  D620N  mutation  of  the  VPS35  gene  were  detected  among  the  PD  cases  or
the  controls.
Even though  these  results  suggest  that the studied  mutations  are  quite  rare  in  SPD patients,  the most
frequent  L444P  mutation  of the GBA  gene  may  be associated  with  the  development  of EOPD  in  the
Hungarian  population.
© 2015  Elsevier  Ireland  Ltd.  All  rights  reserved.
1. Introduction
The most prominent neuropathological features of Parkin-
son’s disease (PD), the second most common neurodegenerative
disorder, are the loss of dopaminergic neurons in the sub-
stantia nigra pars compacta and the presence of Lewy bodies,
although the precise pathomechanism is still not fully understood.
Gene–environment interactions are certainly implicated in the
multifactorial pathogenesis of PD [6].
∗ Corresponding author. Fax: +36 62 545597.
E-mail address: klivenyi.peter@med.u-szeged.hu (P. Klivényi).
The majority of PD cases are sporadic; only 15–20% of the
cases are identiﬁed as familial. In the background of these familial
cases, numerous mutations have been identiﬁed in several genes
that cause autosomal dominant (PARK1, PARK3, PARK4, PARK5,
PARK8 and PARK11) or autosomal recessive (PARK2, PARK6, PARK7,
PARK9, PARK14 and PARK15) forms of PD [9]. The D620N mutation
in the vacuolar protein sorting-associated protein 35 (VPS35) was
recently discovered as a new cause of PD [12]. Furthermore, genetic
risk factors have been identiﬁed in sporadic forms of PD (SPD) [9].
The gene coding for glucocerebrosidase (GBA) has been reported to
have a potential role in the development of PD [5].
Gaucher’s disease (GD) is an autosomal recessively inherited
glycolipid storage disorder caused by a deﬁciency of the lysosomal
http://dx.doi.org/10.1016/j.neulet.2015.11.001
0304-3940/© 2015 Elsevier Ireland Ltd. All rights reserved.
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enzyme GBA. Several studies have reported a clinical, neuropatho-
logical or genetic association between GD and PD [5,8,20].
The GBA gene is localized at chromosome 1q21 and has more
than 300 mutations [16]. Numerous genotyping studies have
demonstrated associations between several GBA mutations and
PD in different ethnic groups. As an example, the frequencies of
GBA mutations in PD patients were highest amongst Ashkenazi
Jews (ranging from 13.7% to 31.3%) [1,7,13]. Furthermore, several
studies have indicated that a high frequency of GBA mutations is
related to an increased risk of PD amongst Japanese, Canadian,
Portuguese, Greek, Norwegian, Italian, Serbian and Chinese pop-
ulations [4,11,18,25,26,28,35,38,41].
N370S has been demonstrated to be the most common muta-
tion among Ashkenazi Jewish PD patients (14.1%), and it is also the
most frequent mutation in several European (e.g. Serbian (1.9%),
French (2.9%) and Portuguese (2.2%)) populations [4,18,20,32]. A
Japanese study detected a signiﬁcant association between the
R120W mutation and PD [25]. L444P is the most common vari-
ant among non-Ashkenazi Jewish patients. The possible association
between this mutation and PD has been investigated in a number
of studies [23,38,39,41].
The VPS35 gene, which is involved in the development of many
neurodegenerative diseases, including Alzheimer’s disease and PD
[12,33], is localized to 16q11.2, and various mutations have been
reported in it [40]. The VPS35 protein is a key component of the
retromer complex which mediates the retrograde transport of pro-
teins from endosomes to the trans-Golgi network [3]. Amongst
the mutations of the VPS35 gene, the D620N missense mutation
has been reported to be pathogenic for PD [37,42], mainly in the
autosomal dominantly inherited cases, but it has additionally been
detected in some sporadic PD cases [2,19,21,31,37,42]. A recent
multicentre study determined the frequencies of VPS35 mutations
in PD in various populations. The D620N mutation was found in 5
familial and 2 sporadic cases [30]. In contrast, other studies suggest
that there is no such mutation in SPD in the Caucasian population
[19,31].
No study has been conducted previously to assess the frequency
of GBA or VPS35 gene mutations in Hungarian PD patients. The
aim of the current preliminary study was therefore to investigate
whether any of the L444P, N370S and R120W mutations of the
GBA gene or the D620N mutation of the VPS35 gene is present in
SPD in the Hungarian population, which belongs in the Caucasian
race.
2. Material and methods
2.1. Subjects
124 SPD patients (mean age: 66.5 ± 9.5 years) were enrolled
in the study. The mean age at onset of PD was 59.1 ± 10.9 years.
Early-onset PD (EOPD) was deﬁned as an age at onset ≤60 years (67
subjects) and late-onset PD (LOPD) as an age at onset >60 years (57
subjects). All of the patients were examined by movement disorder
specialists, who conﬁrmed the diagnosis of SPD. Secondary forms
of parkinsonism were excluded. The PARK2 and PARK8 mutations
were not present in the assessed patient population.
The control group comprised 122 volunteer individuals (mean
age: 64.3 ± 8.2 years) who had no history of neurological or psy-
chiatric disorders (Table 1). All the patients with SPD and all the
controls were of Hungarian origin and were enrolled in the Depart-
ment of Neurology at the University of Szeged.
The study protocol was approved by the Medical Research Coun-
cil Scientiﬁc and Research Ethics Committee (47066-3/2013/EKU
(556/2013)) and all study participants gave their written informed
consent in accordance with the Helsinki Declaration.
Table 1
Characteristics of groups of PD patients and controls.
PD group Control group
No. 124 122
Age (years, mean ± SD) 66.5 ± 9.5 64.3 ± 8.2
Age  at onset ≤60 years 67 (54%)
Age at onset >60 years 57 (46%)
2.2. DNA isolation
Genomic DNA was  extracted from peripheral blood by a stan-
dard desalting method [24], and stored at −20 ◦C until further use.
2.3. Analysis of GBA mutations
The L444P, R120W and N370S polymorphisms of the GBA gene
were determined in all the patients and the controls by using
the polymerase chain reaction and restriction fragment-length
polymorphism (PCR-RFLP) techniques. Three previously described
primer pairs were used separately to amplify the DNA region of
each mutation [1,39]. The PCR primers, annealing temperatures,
restriction enzymes and fragment lengths are listed in Table 2. The
digested products were separated by agarose gel electrophoresis.
2.4. Detection of VPS35 mutation
The D620N mutation in the VPS35 gene was  determined by PCR-
RFLP. The PCR conditions and primers were as described previously
[34]. The PCR products were digested with the HinFI restriction
enzyme (Thermo Scientiﬁc, Waltham, MA,  USA) at 37 ◦C for 30 min.
The digested products were separated by agarose gel electrophore-
sis. The genotypes were deﬁned as GG (257 bp, 231 bp, 139 bp,
74 bp, 18 bp), GA (257 bp, 231 bp, 213 bp, 139 bp, 74 bp, 18 bp) or
AA (257 bp, 231 bp, 213 bp, 18 bp).
2.5. Statistical analysis
SPSS software version 22.0 was applied for the evaluation of the
data populations. The genotype frequencies in the patients and the
controls were analysed by using the Fisher exact test. The normality
of the data was checked with the Kolmogorov–Smirnov test. Since
the data exhibited Gaussian distribution, and the Levene test did not
reveal signiﬁcant differences in the homogeneity of variances, we
applied the independent t test for the comparison of the difference
in age between the PD groups and the controls. Odds ratio (OR)
and 95% conﬁdence intervals (95% CI) were calculated to test for
an association between the GBA mutation and PD. A p value of less
than 0.05 was  considered statistically signiﬁcant.
3. Results
3.1. GBA gene mutations
Amongst the PD patients, 3 individuals (2.4%) carried a heterozy-
gous mutant GBA allele: in all 3 cases the L444P substitution. In
contrast, no mutations were detected in the control group. The
difference in mutation frequencies between the patients (2.4%)
and controls (0%) was  not statistically signiﬁcant (p = 0.247). How-
ever, the carriers of the GBA mutation were at an increased risk of
developing PD (OR = 6.05, 95% CI 0.300–122.06). Moreover, all the
patients who  carried the mutant allele were in the EOPD group.
The frequency was  signiﬁcantly higher in the EOPD group than in
the controls (p = 0.042). However, a comparison of the frequency
between the EOPD group and the LOPD group failed to reveal any
difference (p = 0.247).
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Table  2
Primers, PCR conditions and restriction enzymes used for the detection of GBA mutations.
Mutation Primer sequence Annealing temperature (◦C) Restriction enzyme PCR (bp) Wild type (bp) Mutant (bp)
L444P F:5′-GGAGGACCCAATTGGGTGCGT-3′
R: 5′-ACGCTGTCTTCAGCCCACTTC-3′
59 NciI 637 637 535,102
R120W F:5′-GCAGAGTCCCATACTCTCCT-3′
R:5′-TGGGTGACAGAGAGAGAGACT-3′
56 NciI 836 454,300,82 536,300
N370S F: 5′-GCCTTTGTCCTTACCCTC†G-3′
R: 5′-GACAAAGTTACGCACCCAA-3′
53 XhoI 105 105 89, 16
†  A mismatch was  introduced in the primer at one nucleotide to create a restriction site.
Neither the R120W nor the N370S variant of the GBA gene was
identiﬁed among the assessed PD cases and controls.
3.2. VPS35 gene mutation
The common VPS35 D620N mutation was not detected either in
the PD patients or in the controls in the assessed population.
4. Discussion
PD is a heterogeneous disorder. The majority of PD cases
(75–80%) are sporadic; the remaining 15–20% of the patients have
a familial history. Sporadic PD may  result from complex interac-
tions between genomic and environmental factors. Genome-wide
association studies (GWAS) are carried out to identify rare genetic
variants that increase the risk of PD. Multiple GWAS on PD patients
and controls have revealed numerous loci, including GBA and
MAPT, as risk factors for sporadic PD [36].
Moreover, several genes (PARK1–18) have been identiﬁed that
can cause autosomal dominant or autosomal recessive forms of
PD [17]. They include some genes which play an important role
in the pathogenesis of SPD [10,22]. The D620N mutation in VPS35
(PARK17) was recently discovered as a new cause of PD, mainly in
the autosomal dominantly inherited cases, although it may  addi-
tionally have a role in SPD, but the results are inconsistent [37,42].
In the present study, we examined the three common mutations
(L444P, N370S and R120W) of the GBA gene and the D620N muta-
tion of the VPS35 gene in the Hungarian population (124 patients
with SPD and 122 controls).
Several studies have reported that the frequencies of GBA muta-
tions are higher in PD patients (5–10%) than in controls, but the
range varies in different ethnic groups [29]. Our results indicated
that the PD patients demonstrated a higher frequency (2.4%) of the
L444P mutation of the GBA gene as compared with the controls
(0%), although the difference was not signiﬁcant. This ﬁnding is
similar to those of previous studies that have reported associations
between the L444P mutation and PD [23,38,39]. The L444P muta-
tion was shown to occur with incidences of 2%, 1.39% and 1.14%
amongst American non-Jewish, Canadian and British PD patients,
respectively [8,27,28]. Moreover, an Eastern Canadian study con-
cluded that the frequency of L444P was higher among PD patients
(3.1%) than among controls [15].
A number of studies have found that GBA mutations may  be
considered a risk factor, mainly in EOPD cases [8,14,39]. Our study
revealed that all the patients who carried the mutant allele were
in the EOPD group. These data emphasized the signiﬁcance of the
GBA mutation, particularly in EOPD cases.
Besides the L444P mutation, the other two most frequent muta-
tions in non-Ashkenazi Jewish patients are N370S and R120W [32],
and we therefore investigated these two GBA mutations too. We  did
not detect either the R120W or the N370S variant of the GBA gene
among the PD cases or the controls, although the N370S mutation
was earlier demonstrated in some European PD patients [18,26,32].
These diverse data suggest that the Caucasian population is not
homogeneous in this respect.
Mutations in the VPS35 gene have been identiﬁed as a causative
factor of the development of PD. The mutation carriers have been
estimated to account for less than 1% of the PD population [19].
These mutations have been examined in a number of Caucasian
populations, with different results [19,30,31,37]. We  therefore
investigated the presence of the D620N mutation of the VPS35 gene
in SPD patients, but we were unable to identify this mutation in any
of the patients or controls. This suggests that the D620N mutation
of the VPS35 gene is at best a rare cause of SPD.
The differences between the results of the various studies might
stem from the different sample size and the different study popu-
lations with the possibility of certain ethnic variations.
The genetic causes and risk factors of PD may serve as impor-
tant tools through which to attain a better understanding of the
pathomechanism. Since a genetic background is presumed in the
development of SPD in some cases, it is important to investigate
the different genetic factors in the various SPD populations, which
may  permit the development of new therapeutic targets. Further-
more, the identiﬁcation of novel genetic risk factors may  facilitate
a better selection of homogeneous subpopulations for therapeutic
studies.
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